These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 22176384)

  • 21. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.
    Choi CH; Jo SY; Park HJ; Chang SK; Byeon JS; Myung SJ
    J Clin Gastroenterol; 2011 Sep; 45(8):679-83. PubMed ID: 21301358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.
    Bensoussan A; Kellow JE; Bourchier SJ; Fahey P; Shim L; Malcolm A; Boyce P
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1946-54.e1. PubMed ID: 26133902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.
    Tack JF; Miner PB; Fischer L; Harris MS
    Aliment Pharmacol Ther; 2011 Oct; 34(8):868-77. PubMed ID: 21883322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stool characteristics and colonic transit in irritable bowel syndrome: evaluation at two time points.
    Shim L; Talley NJ; Boyce P; Tennant C; Jones M; Kellow JE
    Scand J Gastroenterol; 2013 Mar; 48(3):295-301. PubMed ID: 23320464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patients suspected of irritable bowel syndrome--cross-sectional study exploring the sensitivity of Rome III criteria in primary care.
    Engsbro AL; Begtrup LM; Kjeldsen J; Larsen PV; de Muckadell OS; Jarbøl DE; Bytzer P
    Am J Gastroenterol; 2013 Jun; 108(6):972-80. PubMed ID: 23419383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
    Singh P; Staller K; Barshop K; Dai E; Newman J; Yoon S; Castel S; Kuo B
    World J Gastroenterol; 2015 Jul; 21(26):8103-9. PubMed ID: 26185382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kiwifruit improves bowel function in patients with irritable bowel syndrome with constipation.
    Chang CC; Lin YT; Lu YT; Liu YS; Liu JF
    Asia Pac J Clin Nutr; 2010; 19(4):451-7. PubMed ID: 21147704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin.
    Shekhar C; Monaghan PJ; Morris J; Issa B; Whorwell PJ; Keevil B; Houghton LA
    Gastroenterology; 2013 Oct; 145(4):749-57; quiz e13-4. PubMed ID: 23872499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece.
    Katsinelos P; Lazaraki G; Kountouras J; Paroutoglou G; Oikonomidou I; Mimidis K; Koutras C; Gelas G; Tziomalos K; Zavos C; Pilpilidis I; Chatzimavroudis G
    Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):183-9. PubMed ID: 19212207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype.
    Bertiaux-Vandaële N; Youmba SB; Belmonte L; Lecleire S; Antonietti M; Gourcerol G; Leroi AM; Déchelotte P; Ménard JF; Ducrotté P; Coëffier M
    Am J Gastroenterol; 2011 Dec; 106(12):2165-73. PubMed ID: 22008894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of biofeedback therapy in dyssynergic defecation patients with and without irritable bowel syndrome.
    Patcharatrakul T; Gonlachanvit S
    J Clin Gastroenterol; 2011 Aug; 45(7):593-8. PubMed ID: 21346602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome.
    Sadik R; Björnsson E; Simrén M
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):102-8. PubMed ID: 19701093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The epidemiology of irritable bowel syndrome in Denmark. A population-based survey in adults ≤50 years of age.
    Krogsgaard LR; Engsbro AL; Bytzer P
    Scand J Gastroenterol; 2013 May; 48(5):523-9. PubMed ID: 23506174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different segmental transit times in patients with irritable bowel syndrome and "normal" colonic transit time: is there a correlation with symptoms?
    Bouchoucha M; Devroede G; Dorval E; Faye A; Arhan P; Arsac M
    Tech Coloproctol; 2006 Dec; 10(4):287-96. PubMed ID: 17115321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is-it possible to distinguish irritable bowel syndrome with constipation from functional constipation?
    Bouchoucha M; Devroede G; Bon C; Bejou B; Mary F; Benamouzig R
    Tech Coloproctol; 2017 Feb; 21(2):125-132. PubMed ID: 28066860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM; Shiff SJ; Quigley EM
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Episodic nature of symptoms in irritable bowel syndrome.
    Palsson OS; Baggish J; Whitehead WE
    Am J Gastroenterol; 2014 Sep; 109(9):1450-60. PubMed ID: 24980882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Further characterization of painful constipation (PC): clinical features over one year and comparison with IBS.
    Drossman DA; Morris C; Hu Y; Leserman J; Dalton C; Toner B; Diamante N; Bangdiwala S
    J Clin Gastroenterol; 2008; 42(10):1080-8. PubMed ID: 18949838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.